Skip to main content

Table 1 OS’s comparisons in recent studies

From: From IB2 to IIIB locally advanced cervical cancers: report of a ten-year experience

Study Centre Number of patients Median age (years) FIGO IB2 (%) FIGO II (%) FIGO III (%) FIGO IV (%) Pelvic LNI (%) Lombo aortic LNI (%) Median/Mean follow-up (months) DFS % (CI 95%) OS % (CI 95%) DSS % (CI 95%)
Present study Saint Etienne, France 94 63 10.6 73.3 16 0 34.1 0 43.9/54.3 56.7 (46.9–68.5) 61.9 (52.3–73.2) 68.5 (59.2–79.2)
Sturdza, [6] International cohort 731 53 16.8 55.9 22.9 3.1 40.5 43 65 73
Touboul, [5] Villejuif, France 150 47 32 61 7 0.7 32.7 0.7 −/43.2 66 (57–74) 71 (61–78)
Haie-Meder, [8] Villejuif, France 84 46.5 23.8 44 26.2 6 36.9 53/− 57* (43–69) 52* (40–64)
Han, [21] Toronto, Canada 7359 55 (mean) 8.2 52.5 35.8 3.5 40.8/− 58.2* (with brachytherapy), 46.2* (without) 64.3* (with brachytherapy), 51.5* (without)
Magne, [14] Villejuif, France 113 76 3.5 (31% IA and IB1) 45,1 16,8 3.6 14.2 6.2 37.2/− 81** (72–88) 88.6** (77–92)
Gouy, [7] Villejuif, France 237 46 33 55 10 2 21 30/− 71** (63–78) 78** (64–88)
Song, [28] Chicago, US 113 49 19 57 24 0 17 0 26/− 58** (49–67) 66** (57–75) 74** (66–82)
Chargari, [37] Villejuif, France 45 50 31.1 51 13.3 4.4 51.1 8.9 26/26.7 73*** 78***
  1. Pathological lymph nodes were defined as lymph nodes > 1 cm in size, loss of oval shape on imaging, or positive on PET-CT imaging
  2. Survivals are given at 5-year, 4-year (*), 3-year (**) or 2-year (***)
  3. Abbreviations: FIGO International Federation of Gynecology and Obstetrics, LNI lymph node involvement, DFS Disease-Free Survival, OS Overall Survival, DSS Disease-Specific Survival, PET-CT Positron Emission Tomography-Computed Tomography